Zevra Therapeutics, Inc. (ZVRA) Earnings Call Transcript & Summary
August 11, 2022
Earnings Call Speaker Segments
Nichol Ochsner
executiveThanks. Good afternoon, everyone, and I appreciate you being on this call as we go over KemPharm's financial and corporate results for the second quarter of 2022. Before we get started, I want to remind those listening that things said on this call could include forward-looking statements involving risks and uncertainties, and those may change at any point in time, including, but not limited to, statements concerning KemPharm's expectations about future operating results. These forward-looking statements are provided under the safe harbor protections of the federal securities laws and reflect what management currently expects. Results could actually turn out to be materially different. Except where the law requires it, KemPharm takes on no obligation to update or revise forward-looking statements. Additional details about forward-looking statements, risks, and uncertainties appear in KemPharm's SEC filings, which you can access on the company's website in the Investor Relations section. On the call today we'll hear from Travis Mickle, who serves as KemPharm's President and CEO, and from LaDuane Clifton, our CFO. We're also delighted to be joined by Perry Sternberg, President and CEO of Corium Inc., who will give an update on AZSTARYS commercialization. After their remarks, Travis and LaDuane will take part in a question-and-answer session; so with that, I'm happy to introduce Travis.
Travis Mickle
executiveThanks, Nichol. And thanks to all of you for being with us once more today; it's a pleasure to have Perry joining us on this call about our second quarter results. I'll also be sharing a few updates on product development myself, along with the usual financial review from LaDuane, our CFO; so at this point I'm going to hand things to Perry after just a brief introduction. Perry is a leader in the biotechnology and pharmaceutical industry who brings over 25 years of commercial experience spanning a broad range of therapeutic areas and varied markets. Before coming to Corium, Perry held a dual position at Shire, serving as Head of Commercial for seven therapeutic area business units and also as Chief Commercial Officer/Head of the Neuroscience Division prior to Takeda's acquisition of Shire in early 2019. It's been a pleasure to know Perry for a number of years; and naturally we collaborate closely as partners on AZSTARYS. So with that, Perry, I appreciate you being part of this and I'll let you take it from here.
Perry Sternberg
executiveI appreciate that introduction, Travis, and thanks for having me share where things stand with Corium's commercialization efforts for AZSTARYS. This is an incredibly thrilling and hectic period for everyone here at Corium, so I'd like to kick things off with a quick snapshot of the company. Moving to the next slide. I'm happy to report that across the past several years, Corium has reinvented itself, going from mainly a CDMO — a contract development and manufacturing organization — to a fully integrated pharma business that develops, produces, and today markets novel CNS therapies. An affiliate of Gurnet Point Capital, a top health care private equity firm, has held ownership of Corium since late 2018. Our offices and a manufacturing site are located in Grand Rapids, Michigan, and we also have offices in Boston, Massachusetts. We've built a veteran leadership group possessing deep ADHD expertise, counting several individuals who formerly spent time at Shire and contributed to launching and growing Vyvanse into a blockbuster. Two CNS products have recently won approval and are now being commercialized by us: AZSTARYS, cleared by the FDA in March 2021 to treat ADHD; and ADLARITY, a transdermal patch delivering donepezil, cleared in March 2022 for dementia of the Alzheimer's type. Our CDMO business operates out of Grand Rapids, bringing industry-leading know-how in transdermal development and manufacturing, producing multiple consumer and FDA-approved drug products, among them our very own ADLARITY. That covers the quick snapshot of Corium. On to the next slide, please. Regarding AZSTARYS, as I noted, the FDA cleared it in March 2021 to treat ADHD in patients six years of age and older; what sets it apart from every other ADHD medication is its composition of 70% serdexmethylphenidate, a novel prodrug of d-methylphenidate, plus 30% of d-methylphenidate, delivering both immediate and sustained benefit across the day. AZSTARYS carries a Schedule II controlled substance classification, though the 70% SDX portion is Schedule IV. It stands as the first and only approved methylphenidate drug to include the prodrug; feedback from HCPs on the product profile has been extremely favorable. AZSTARYS gives us a lengthy exclusivity runway, with strong patent protection running until at least 2037, and we believe it qualifies for regulatory exclusivity. Next slide. The AZSTARYS launch has performed extremely well; prescriptions have grown steadily through the market introduction phase, both in breadth and depth — meaning a growing number of physicians write for AZSTARYS, and those who do write for it are writing more of it; beyond that, a rising count of pharmacies have been ordering AZSTARYS across the geographies where our sales representatives are present. Our strategy for launching AZSTARYS has been highly deliberate, drawing on lessons from other product launches, with the initial launch during 2021 and early 2022 concentrated on geographies with product coverage, and we expanded the field force to match our coverage wins; those efforts have paid off. So because of that, by July of this year, we've got a national footprint now with roughly 175 sales reps, and last month we held our very first AZSTARYS national sales meeting. Our experienced market access group has achieved quite a lot, reaching 145 million patient lives with preferred status covering more than 35 million lives. Beyond taking the launch national, we're also sharpening our commercial team's attention on the sizable adult market, especially since the Vyvanse field force supported by Takeda has been withdrawn. So now we're concentrating on both pediatric and adult markets, which we'll demonstrate commercially and, more importantly, deliver advantages to the patients and caregivers we support. That's the short version. To finish my update, everyone at Corium is delighted with what we've accomplished in the CNS area and with our evolution into a fully integrated pharmaceutical company. Our AZSTARYS launch has performed as well as expected, maybe even better, and we're quite hopeful about where our business is headed. I'd like to thank Travis for the chance to give this update on Corium and AZSTARYS, for being on this call, and for working alongside KemPharm. Travis, over to you.
Travis Mickle
executiveAbsolutely, and thank you so much, Perry, for spending time with us. I really appreciate how thorough and how prompt that update was regarding AZSTARYS and its commercial launch. So once again, many thanks for your time. Feel free to sign off whenever you'd like. Now I'd like to shift to the KemPharm updates we have for today. Very quickly, for anyone who might be unfamiliar with the KemPharm story, the company has truly undergone an extraordinary transformation. In the beginning we were a prodrug drug discovery organization, then we evolved into development, and eventually we gained partners — one of which you just heard about, AZSTARYS. And today we stand with a late-stage CNS-focused rare disease product. We also have a mid-stage opportunity, plus of course revenue potential, through partnerships that are already established. This transformation isn't finished. Our balance sheet is strong. Any number of these products could allow us to transform the organization yet again, this time into a commercial entity. So from early-stage drug discovery all the way to a possible commercial launch, we could become a commercial company that represents a genuine value proposition — and that is what KemPharm offers us today. If we look at some recent highlights, you can begin to truly observe that transformation taking shape, or unfolding, right in front of you. The latest news that I think everyone ought to be well aware of, if you follow the story, is the arimoclomol acquisition. This was an NDA-stage asset that became available to us due to certain difficulties arimoclomol encountered with the CRL related to treating Niemann-Pick type C, or NPC. Through a highly capital-efficient structure, we were able to secure this asset, effectively enabling the prospect of future positive cash flow while also avoiding any shareholder dilution whatsoever. It was certainly a very smart financial transaction. Beyond just acquiring this asset, we also may be able to refile the NDA as early as the first quarter of next year. So once again, we moved from a product that had just been approved — AZSTARYS — to a mid-stage asset known as KP1077 for idiopathic hypersomnia, and now to a late-stage product with an NDA resubmission in the first quarter of next year. Let me also highlight KP1077, our other development-stage asset, which targets idiopathic hypersomnia. Everything in our development program remains on track. We will officially begin a Phase II trial during the second half, which, of course, we are already in. Work around this has already started, and I'll share a few additional details. We also anticipate seeing results from a cardiovascular trial we kicked off last quarter, and those topline results ought to be available at some point this quarter. And we have that highly pertinent update from Perry regarding the AZSTARYS launch. There's a lot of excitement around how our sales rep numbers are climbing and how much broader our coverage has gotten, and that really sets up what's ahead when it comes to royalties and milestones. Beyond that, as I noted earlier, we're sitting on a solid balance sheet, with cash and cash equivalents of about $114.5 million at the close of the quarter, plus room to bring in additional revenue down the road from a variety of places. With those points in mind, I'll spend a moment going over a few of our development-stage assets, beginning with arimoclomol, which is the furthest along. This is somewhat of a recap. Nothing here represents any real shift from what we've shared previously regarding arimoclomol. It's a therapy for an ultra-rare condition called Niemann-Pick type C, or NPC for short; this is a lysosomal storage disorder that is disabling and fatal. The main symptoms, or problems, tied to Niemann-Pick type C involve neurological issues, which is exactly why we feel those neurological symptoms are familiar territory for us, given our work with other CNS disorders, and why they suit our expertise and our development capabilities so well. At present, no approved treatments for NPC exist in the United States. I've already brought up how capital efficient — how efficient the financial structure behind the acquisition is. The upside we see comes in several forms. First, this is a late-stage candidate, which lets us transform on the commercial side. It also gives us a chance to showcase our internal expertise, which lies in developing assets that perhaps aren't especially appealing to other organizations, or ones that have encountered their own development hurdles. Here at KemPharm, we had the case of APADAZ and the CRL that came out. We pursued an appeal and in the end secured approval for that product and brought in a partner. Given that it was an opioid, that's quite an achievement. AZSTARYS ran into trouble with statistical analysis; we collaborated closely with our partner at Corium to assist them with their ADLARITY program; so those two situations really show you what we think KemPharm's future holds — a robust development organization that transforms and layers on commercial capability as part of that value proposition. Arimoclomol additionally has several early access programs open to it in the U.S., France and Germany, mainly in other European countries; in France, this is a very progressive and intriguing system where they permit reimbursement ahead of approval for certain rare diseases with an unmet need. Under the French EAP system right now, we estimate we bring in about $12 million per year in annual gross revenue through that program. LaDuane will share a few more updates on how that looks and how it might be applied within the financial structure we used to acquire the asset. Turning now to what's ahead with arimoclomol, once again we have this near-term chance to commercialize the asset; and I haven't actually offered any forward-looking thoughts here. This is an ultra-rare disease. So we're aware that there are around 300 patients who have been identified, to put it plainly. A good number of those individuals belong to a patient registry. Every one of them receives care from specialists located at different centers across the nation. Because of that, putting together a suitable commercial team to connect with each of these patients isn't all that hard, and naturally that includes all the thought leaders, clinicians, and everybody else engaged in those efforts. That's the reason it's wonderful to begin with a condition such as Niemann-Pick as your initial treatment opportunity: first, the patients; second, to grow as a commercial — into commercializing your very own products. This reduced marketing expenditure truly, truly assists you in accomplishing that; I haven't encountered worries from different shareholders that we'll turn into Pfizer overnight with hundreds of sales reps. That simply isn't how it works with conditions like Niemann-Pick and even conditions like Idiopathic Hypersomnia with KP1077; we already possess a network of established relationships via our early access programs in both the U.S. and the EU, and we think these will prove essential as we consider commercializing and moving forward at some point and ideally very soon with an approved product. And then as we look beyond the U.S.
Travis Mickle
executiveAnd within the EU, additional nations, territories, and regions could hold appeal for us regarding a range of partnership and licensing possibilities involving arimoclomol. That's just a quick sketch of where our heads are at when we describe arimoclomol as potentially the chance we've sought to move KemPharm forward into its next phase of growth. Shifting to KP1077 now — something I've brought up a number of times — this is our potential therapeutic treatment for Idiopathic Hypersomnia. It's an uncommon sleep condition where people are unable to get fully restorative sleep. They might sleep 10, 12, 14 hours, take several naps, and still feel constantly as though they're in a fog. So they experience this brain fog and face tremendous difficulty getting their day started. Waking up is therefore among the main problems; this candidate is in fact 100% of the prodrug Perry referred to. Excellent way to introduce the product, 1077, for us, Perry. Serdexmethylphenidate here makes up 100% of the active ingredient, unlike a combination such as AZSTARYS. And at significantly larger doses — we expect it will be given at significantly larger doses — to tackle the core symptoms of idiopathic hypersomnia, which are both serious and utterly disabling for these patients. This product qualifies for fast-track, orphan drug, and breakthrough designation. And a great deal of it involves the same or comparable IP, just as Perry explained. Nobody is better suited to explain your intellectual property than the individual who licensed it; so having that confirmation on this slide makes us very excited. What I haven't gone into much detail about regarding KP1077 is that the dosing we're concentrating on here is truly meant to target the symptoms. So it will either be given once at night for those who struggle most with waking, or it will be given twice daily; once at night for waking and once in the morning to assist with the brain fog that arises across the day. Now, we do recognize that the majority of patients experience both, yet there's a subset for whom it seems that only sleep waking is their main problem, and then they manage reasonably well for the remainder of the day. So we think that through our ongoing Phase II study, we'll genuinely be able to tackle and determine which symptoms respond best and where KP1077 would be most appropriate for treating those patients. Since we intend to use a larger dose, we do recognize that some work is required, and we began that study in the previous quarter. That's a study examining the lower cardiovascular effects of KP1077, or SDX, compared with those of other stimulants; so at a matching dose of eribulin LA. Do we do better, the same, or worse than those matching doses when it comes to cardiovascular effects such as blood pressure and heart rate? Our expectation is that performance will be stronger, and that should translate into better tolerability, which lets us keep escalating the dose, and in the end that ought to deliver a bigger benefit in this condition. There are also, as we're aware, several medicines prescribed off-label that address a portion of these same symptoms. With SDX specifically, there's no potential for drug-drug interactions involving hormonal contraceptives or antidepressants; those are among the other agents that could, naturally, be used off-label for treating IH. To sort of bring this to a close, I'd like to convey our view of the clinical and regulatory milestones ahead that matter most to the audience listening here. On Arimoclomol, I've already noted the anticipated Q1 2023 refiling of the NDA for NPC. Several of our objectives for KP1077 in IH have now been met. The Type B meeting wasn't included on this list; we submitted the IND. The CV trial is running and ought to report out during this quarter. We already have preliminary results; it's simply a matter of assembling it all so we can share it. The Phase II trial has begun, with protocol development, recruitment planning, and CRO selection all finished. First patient dosing should therefore come before the year ends; that study will continue for some time. Yet, as I said earlier, we expect that around Q2 or Q3 we'll have open-label interim results along with top line data prior to the close of 2023. After the IH indication, our plan is to take KP1077 into narcolepsy; that will trail whatever we're doing in IH by approximately a quarter. Once again, since it's the same FDA division, we need them completely informed, chiefly that the indication we're pursuing is IH and that our narcolepsy program will be used to back the IH approval and the later addition of the narcolepsy indication onto that label. That means we can't run them at the same time. They have to be staggered in this manner, and we believe that's the reason it comes out that way. I think that covers all the updates worth mentioning. We'll obviously get to questions afterward, but right now I'm going to pass things to LaDuane for our financial update.
La Duane Clifton
executiveThanks, Travis, and good afternoon. Our financial position remains very strong, and Q2 turned out to be another set of solid results, as we expected. For the quarter, net revenue came to $1.3 million. That figure comes from Arimoclomol product sales, consulting service fees, and royalties; it represents a shift in revenue compared with earlier quarters, and as we've mentioned to you previously, we anticipated that consulting service fees would decline as that contract wrapped up. We still have a smaller scope on that front, but it truly won't be a main revenue driver going forward. And naturally, Q2 revenue includes just one month of Arimoclomol product sales — only June, since the deal closed on May 31. So you should expect a growing contribution from that revenue in upcoming quarters, when you'll get a full three months in each one. Turning to the net loss for Q2, it was $24 million, or $0.70 per share. However, that figure included a one-time non-cash expense tied to the Arimoclomol asset acquisition. Most of that purchase price gets written off on a non-cash basis, which I believe is probably beneficial for us down the road, but that's where the accounting guidance took us. If you factor that out, you get a non-GAAP net loss of just $6.4 million, or $0.19 per basic and diluted share, which I think matters more when you're examining net income and net loss trends. On the balance sheet as of June 30, we're still in a very strong spot. And as Travis said, we ended the quarter with $114.5 million in cash, which is very strong. That's a decrease of roughly $4.6 million from where we stood at the close of Q1. And once again, this is roughly consistent with what we expected. We knew R&D spending would rise as the 1077 program moves forward, so all the work Travis described is work we started during Q2, and you can see that increase there. But in later quarters too, I think you'll keep seeing a cash burn rate probably somewhere between $4 million and $6 million per quarter. And again, that fits very comfortably within our operating expectations. As for the line of credit, Travis mentioned we brought it in as a novel, genuinely creative way to preserve capital flexibility. Since arimoclomol's purchase keeps generating money coming in, we decided to tap a credit facility that this income can cover, which frees up our own funds for other purposes; that provides room to maneuver for our operational strategy and every development goal we plan to hit, plus the possibility — should any business development chances arise, we retain that same room to maneuver thanks to a healthy balance sheet for such uses too. Our available cash continues looking quite robust and truly extends past 2025, and honestly this is what distinguishes us from competitors in the field, since we face no pressing requirement to go out and raise money. To put a finer point on it, the funds sitting on our balance sheet along with this runway let us finish what's needed to, with luck, secure approval for arimoclomol. It additionally lets us perform every bit of development activity and advance 1077 all the way to an NDA filing; thus, we sit in an excellent spot and I believe on account of all these factors we feel tremendous enthusiasm regarding what lies ahead for KemPharm. So Travis, I suppose right now we should proceed and hand things over for questions. Operator, please open the Q&A.
Jonathan Aschoff
analystThanks for that, and good afternoon, everyone. What would you say are the riskiest elements, if any, when it comes to the arimoclomol refiling?
Travis Mickle
executiveJonathan, Travis here. Great question. Ever since we completed the acquisition, we've devoted the overwhelming bulk of our time to examining every detail, since the deal itself closed on a very compressed timeline. Essentially, the CRL raised 3 major points tied to the validity, or the robustness, of the primary tool used to assess NPC, which is also called the NPCCSS. Second, there's the matter of how efficacy was established through the use of highly statistical approaches — the < >, as they're referred to — to figure out whether an effect existed, and much of that hinges on missing data and similar considerations. Then finally, though certainly not least important, comes confirmatory evidence. Looking across all of it, I can't point to any one item that stands alone without depending on another. I genuinely think there's compelling data generated by the former Orphazyme team, and since the acquisition, working alongside those same people, plus further support via confirmatory evidence, that we tackle every one of these issues. At the core, though, we can't go back and alter the instrument, so if you asked me where the biggest risk still lies, it's in persuading the agency that this constitutes a validated, strong, and robust way of measuring how the disease progresses in NPC.
Jonathan Aschoff
analystAlright, that's useful. Would you mind splitting that $1.3 million across the three categories — AZSTARYS, arimoclomol, and the other non-product line?
La Duane Clifton
executiveJonathan, we'll need to check how we present that breakdown in the 10-Q, but here's what I can share — the French EAP revenue was roughly $1.4 million, and we report it net of a liability we might owe should approval come through. That reduction reflects a discount of around 35%, so with those figures you can sort of work out the remainder. And ideally the 10-Q will give you a bit more detail on that.
Jonathan Aschoff
analystAll right. Do you have any idea when APADAZ revenue might start showing up?
La Duane Clifton
executiveWell, as you're aware, I'd just point out that we licensed that to KVK. Since it's a profit share arrangement, our expectation is that nothing would come to us before KVK reaches a stage where profits exist. By its very design, then, this takes more time than a typical royalty structure would; even so, I would say they keep working toward commercializing APADAZ; right now it remains in quite a small, localized regional footprint, and my belief is that profitability is not close. As a result, I can't give you a time line for when profit share would appear.
Jonathan Aschoff
analystAll right. Then, on the final point, you mentioned a quarterly cash burn of $4 million to $6 million past 2025. Does that mean you anticipate negative cash flow all the way through 2025, or is that not really your expectation, especially with some support from arimoclomol and AZSTARYS?
La Duane Clifton
executiveSure. No, I appreciate that question, since when I assemble and review the cash runway, I aim to use a highly conservative perspective for it; so I think treating the early access revenue as fair to include in your operating forecast makes sense. But because of the — it's tough to estimate the timing around AZSTARYS revenue. So, when I give that figure, I'm considering our cash runway along with our budgeted R&D, plus what the French revenue contributes, and those are the only pieces I'm factoring in. What could exceed that projection would be royalties, royalties coming in stronger than anticipated, or royalties broadly from AZSTARYS, and likewise once those net sales milestones are hit, they'd also add upside beyond that projection. So I'm attempting to present a highly realistic view, yet we also end up in this position, where we're sort of bringing in revenue, but we're still definitely a development-stage company that's continuing; so there comes a moment and we're hopeful it's upon approval of arimoclomol that we'll genuinely turn into a commercialized entity with substantial revenue where we retain most of it, since we'll commercialize on our own; so, but that's how I arrive at that runway.
Jonathan Aschoff
analystThat clears things up a bit for me. Thanks so much.
Travis Mickle
executiveThanks once more, everybody, for being on this call today. I'd like to pull together much of what has been presented to you here. Of course, the transformation has come up. For roughly nine months, you've heard us discuss this from a strategic standpoint for the company — pushing the organization ahead — and considering our current position: a solid financial standing; we hold a partnered asset. You just heard from that partner that it is advancing toward a complete national launch; therefore, the significant potential lies with AZSTARYS royalties and milestones. We also hold a late-stage asset that is already bringing in revenue and essentially covering its own costs, at minimum, in the near term, and it could turn cash flow positive. Beyond that, we have a mid-stage rare disease product, KP1077; that's an extraordinary story. I cannot locate another like it anywhere, given our market cap, our price, and our situation. It's truly astonishing that we find ourselves here with so much opportunity. So without a doubt, we're quite thrilled and trust you feel the same. Once more, I value the time. Thanks, all.
Operator
operatorEveryone, that wraps up the KemPharm Second Quarter 2022 Earnings Call and Webcast for today. At this point you're free to hang up, and we hope your day is a great one.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Zevra Therapeutics, Inc. transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Zevra Therapeutics, Inc. earnings transcripts and 131,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Zevra Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.